期刊
NEUROIMAGE-CLINICAL
卷 2, 期 -, 页码 497-511出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.nicl.2013.03.014
关键词
Flutemetamol; Florbetapir; Florbetaben; PIB; Clinic; Diagnostic
类别
资金
- FWO [G.0076.02]
- KU Leuven Research [OT/08/056, OT/12/097]
- Federaal Wetenschapsbeleid belspo Inter-University Attraction Pole [P6/29, P7/11]
- Stichting Alzheimer Onderzoek grant [11020]
Amyloid imaging is currently introduced to the market for clinical use. We will review the evidence demonstrating that the different amyloid PET ligands that are currently available are valid biomarkers for Alzheimer-related beta amyloidosis. Based on recent findings from cross-sectional and longitudinal imaging studies using different modalities, we will incorporate amyloid imaging into a multidimensional model of Alzheimer's disease. Aside from the critical role in improving clinical trial design for amyloid-lowering drugs, we will also propose a tentative algorithm for when it may be useful in a memory clinic environment. Gaps in our evidence-based knowledge of the added value of amyloid imaging in a clinical context will be identified and will need to be addressed by dedicated studies of clinical utility. (C) 2013 The Authors. Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据